Precision Biologics, Inc. to present at AACR IO 2025, February 24, 2025, Los Angeles, CA

Precision Biologics announces that our Director of Research & Development, Massimo Fantini, PhD, will deliver a Poster Presentation at AACR IO 2025 on a novel strategy to enhance cancer immunotherapy efficacy. The development and characterization of two monoclonal antibodies (NEO-201 and PB-223) that target truncated O-glycans (expressed specifically on cancer cells and not normal tissue) can offer a novel strategy to enhance cancer immunotherapy efficacy.

Two clinical stage monoclonal antibodies (mAbs), NEO-201 and PB-223 (developed through immune engineering of our previous mAb NEO-102) both recognize truncated O-glycans expressed specifically on tumor tissues, sparing healthy tissues. Clinical trial results indicate that NEO-201 demonstrates a manageable safety profile and promising efficacy by facilitating the destruction of both cancer cells and immunosuppressive cells expressing core 1 O-glycans. Flow cytometry and IHC analysis showed that PB-223 binds to a wide spectrum of human tumor types while sparing normal tissues. PB-223 can also internalize into human cancer cell lines expressing core 2 O-glycans. Additionally, NEO-201 and PB-223 serve as versatile platforms for developing next-generation therapeutics, including CAR-T/CAR-NK cells, T-cell/NK cell engagers, bispecific antibodies, and antibody-drug conjugates (ADCs).

A poster will be presented in person at the American Association for Cancer Research Immuno-Oncology (AACR IO) 2025 meeting, JW Marriott Los Angeles L.A. Live, Los Angeles, California, USA, on February 24th 2025 from 1.45pm to 4pm. .

Poster title: “Development of monoclonal antibodies targeting truncated O-glycans expressed specifically by cancer cells offers a novel strategy to enhance cancer immunotherapy efficacy”

Please stop by Poster Session A, poster A009.